Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04957082 · ClinicalTrials.gov registry record · NA

Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake

A NA study of SARS-CoV2 Infection, sponsored by Michigan State University.

Completed
Registry status
NA
Development phase
666
Enrollment target
1
Study location

NCT04957082 is a NA study of SARS-CoV2 Infection that has completed, run by Michigan State University. The registered enrollment target is 666 participants, below the 1,146-participant average among 6 other SARS-CoV2 Infection trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04957082, a NA study of SARS-CoV2 Infection, has completed, sponsored by Michigan State University.

COMPLETED
Registry status
NA
Development phase
666 participants
Enrollment target
1
Study location

Study Summary

This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan. This iteration will consider individuals recruited from the Flint Registry and assess willingness to participate in a drive-up saliva sample collection taking place at a central location in Flint, Michigan.

Conditions Studied

Interventions

  • BEHAVIORAL Culturally Targeted SARS-CoV-2 Communication
  • BEHAVIORAL General SARS-CoV-2 Communication

Study Locations (1)

Michigan

  • Flint Journal Building - Flint

Trial Details

FieldValue
Enrollment Target 666 participants
Start Date 2021-08-04
Est. Completion 2022-12-19
Phase NA

Sponsor

Michigan State University

120 total trials

What the Registry Record Tells You About NCT04957082

The ClinicalTrials.gov registry entry for NCT04957082 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 666 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,146-participant average among 6 other SARS-CoV2 Infection trials with a reported enrollment target (42% lower). The listed sponsor is Michigan State University, which has 120 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with SARS-CoV2 Infection appearing as the primary indexed condition, and to 2 interventions - of which Culturally Targeted SARS-CoV-2 Communication is the first listed.

NCT04957082 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT04957082 about?

NCT04957082 is a clinical study titled "Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake". This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan. This iteration will consider individuals recruited from the Flint Registry and assess...

What is the current status of trial NCT04957082?

This trial is currently completed. It is a NA study. The enrollment target is 666 participants. The study started on 2021-08-04. Estimated completion is 2022-12-19.

What conditions does trial NCT04957082 study?

This clinical trial studies the following conditions: SARS-CoV2 Infection.

What interventions are being tested in trial NCT04957082?

The interventions under investigation include: Culturally Targeted SARS-CoV-2 Communication (BEHAVIORAL), General SARS-CoV-2 Communication (BEHAVIORAL).

Who is sponsoring clinical trial NCT04957082?

This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04957082 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for SARS-CoV2 Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.